Please use this identifier to cite or link to this item:
Type: Artigo
Title: Tafenoquine for the prophylaxis, treatment and elimination of malaria: eagerness must meet prudence
Author: Val, Fernando
Costa, Fabio T. M.
King, Liam
Brito-Sousa, Jose D.
Bassat, Quique
Monteiro, Wuelton M.
Siqueira, Andre M.
Luzzatto, Lucio
Lacerda, Marcus V. G.
Abstract: Malaria puts more than 3 billion people at risk of infection and causes high morbidity and mortality. Plasmodium vivax forms hypnozoites, which may initiate recurrences, even in the absence of reinfection or superinfection. Until recently, the only drug available for eliminating hypnozoites was primaquine (PQ), which, given its short half-life, requires a relatively long course of treatment. Tafenoquine (TQ) is a PQ analog with a longer half-life. This enables radical cure of malaria with a single dose and overcomes adherence issues associated with PQ, thereby increasing effectiveness in real-life settings. Clinical studies have provided sound evidence for TQ's safety and efficacy against malaria, which recently led to its approval by the US FDA. Here, we review aspects of TQ, including how to avoid hemolytic anemia in G6PD deficient patients. We believe that TQ promises to be a major advance toward malaria elimination.
Subject: Malaria
Country: Reino Unido
Editor: Future Medicine
Rights: Fechado
Identifier DOI: 10.2217/fmb-2019-0202
Date Issue: 2019
Appears in Collections:IB - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
000508001400002.pdf1.49 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.